Gara Jalqabaatti › Kansarii Ovarii › Oregon › Portland
Qorannoo klinikaalii Kansarii Ovarii Portland, OR keessatti
Qorannoo 27 Kansarii Ovarii f Portland fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Providence Cancer Institute, Portland
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Namoota walitti qabaa jiraSadarkaa 2/3
- Oregon Health and Science University, Portland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Oregon Health & Science University (OHSU), Portland
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Namoota walitti qabaa jiraSadarkaa 2
- Providence Portland Medical Center /ID# 277727, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Site 02, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- Oregon Health and Science University, Portland
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Namoota walitti qabaa jiraSadarkaa 3
- Providence Cancer Institute Franz Clinic, Portland
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Providence Cancer Institute, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Providence Portland Medical Center, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Namoota walitti qabaa jiraSadarkaa 3
- Site 0105, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Providence Cancer Institute, Portland
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Namoota walitti qabaa jira
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- fi 2 dabalataa
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- fi 2 dabalataa
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Oregon Health & Science University, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Providence Cancer Institute Franz Clinic, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- fi 1 dabalataa
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Namoota walitti qabaa jiraSadarkaa 3
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- USA15-0, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Oregon Health Sciences University, Portland
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Namoota walitti qabaa jiraSadarkaa 2
- SCRI - Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, Portland
Qorannoo Kansarii Ovarii magaalota biroo keessatti
- Houston, TXQorannoo 89
- New York City, NYQorannoo 69
- Boston, MAQorannoo 61
- Los Angeles, CAQorannoo 50
- Nashville, TNQorannoo 49
- Arlington, VAQorannoo 46
- Philadelphia, PAQorannoo 44
- Columbus, OHQorannoo 39
- St. Louis, MOQorannoo 38
- Chicago, ILQorannoo 36
- San Antonio, TXQorannoo 31
- Cleveland, OHQorannoo 30
Qorannoo biroo Portland keessatti
- Kansara Qara'a Non-Small CellQorannoo 46
- Saree (Gosoota Hunda)Qorannoo 34
- Saree OljooQorannoo 33
- Kansarii ProstateQorannoo 33
- Kansara MetastatikiiQorannoo 29
- Kansarii ColorectalQorannoo 28
- Dhibee QaraQorannoo 26
- Leukemia Myeloidii HamaaQorannoo 25
- Kansa EndometiriyaaliiQorannoo 24
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 19
- Kansarii PancreasQorannoo 19
- Cufama OnneeQorannoo 17
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.